Adverum Biotechnologies (ADVM)
(Real Time Quote from BATS)
$7.08 USD
+0.05 (0.71%)
Updated Sep 12, 2024 12:10 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Adverum Biotechnologies, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -117.17 | -154.54 | -145.54 | -117.51 | -64.49 |
Depreciation/Amortization & Depletion | 3.71 | 9.69 | 7.42 | 6.27 | 2.47 |
Net Change from Assets/Liabilities | -8.32 | 15.85 | 4.06 | 11.14 | 2.89 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 30.87 | 20.91 | 26.23 | 20.81 | 9.96 |
Net Cash From Operating Activities | -90.90 | -108.09 | -107.83 | -79.29 | -49.17 |
Property & Equipment | -0.81 | -11.82 | -15.12 | -11.84 | -19.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 97.68 | 153.54 | 93.83 | -268.32 | -48.83 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 96.88 | 141.72 | 78.71 | -280.17 | -68.07 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.49 | 0.61 | 2.64 | 358.09 | 29.77 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.24 | -0.06 | -0.11 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.42 | 0.00 | 0.00 | -2.04 | -1.47 |
Net Cash from Financing Activities | 0.07 | 0.61 | 2.40 | 355.99 | 28.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 6.04 | 34.24 | -26.73 | -3.47 | -89.05 |
Cash at Beginning of Period | 70.93 | 36.70 | 63.42 | 66.90 | 155.95 |
Cash at End of Period | 76.98 | 70.93 | 36.70 | 63.42 | 66.90 |
Diluted Net EPS | -11.60 | -15.60 | -14.80 | -13.80 | -10.10 |
Fiscal Year End for Adverum Biotechnologies, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -43.26 | -24.79 | -117.17 | -93.45 | -60.57 |
Depreciation/Amortization & Depletion | 1.18 | 0.66 | 3.71 | 2.80 | 1.45 |
Net Change from Assets/Liabilities | -9.11 | -3.78 | -8.32 | 7.83 | 4.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.10 | 4.65 | 30.87 | 13.25 | 8.73 |
Net Cash From Operating Activities | -43.09 | -23.25 | -90.90 | -69.57 | -45.66 |
Property & Equipment | -0.11 | -0.09 | -0.81 | -0.62 | -0.12 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -24.25 | -21.94 | 97.68 | 107.37 | 88.68 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -24.35 | -22.03 | 96.88 | 106.75 | 88.56 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 119.76 | 119.88 | 0.49 | 0.25 | 0.25 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.42 | -0.34 | -0.24 |
Net Cash from Financing Activities | 119.76 | 119.88 | 0.07 | -0.10 | 0.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 52.32 | 74.61 | 6.04 | 37.08 | 42.90 |
Cash at Beginning of Period | 76.98 | 76.98 | 70.93 | 70.93 | 70.93 |
Cash at End of Period | 129.30 | 151.58 | 76.98 | 108.02 | 113.84 |
Diluted Net EPS | -0.89 | -1.50 | -2.30 | -3.30 | -3.10 |